According to a post on the FDA’s website, Juno Therapeutics’ lisocabtagene maraleucel received orphan designation. Juno Therapeutics is a Bristol-Myers Squibb company. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers’ Juno get orphan designation for lisocabtagene maraleucel
- Bristol-Myers granted three applications for myeloma candidate Abecma
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Bristol-Myers announces CHMP opinion recommending approval for Breyanzi
- Juno Therapeutics’ lisocabtagene maraleucel receives FDA orphan designation